JAMA Network Open. 2018; 1 (5):e182421; Thacker EL, Chen H, Patel AV, et al. Recreational physical activity and risk of Parkinson’s disease. Movement Disorders. 2008;23(1):69–74.
52. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurology. 2016;15(12):1257–1272; Sun Q, Townsend MK, Okereke OI, Franco OH, Hu FB, Grodstein F. Physical activity at midlife in relation to successful survival in women at age 70 years or older. Archives of Internal Medicine. 2010;170(2):194–201; Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. New England Journal of Medicine. 2002;346(11):793–801; Gebel K, Ding D, Chey T, Stamatakis E, Brown WJ, Bauman AE. Effect of moderate to vigorous physical activity on all-cause mortality in middle-aged and older Australians. JAMA Internal Medicine. 2015;175(6):970–977.
53. Fang X, Han D, Cheng Q, et al. Association of levels of physical activity with risk of Parkinson disease: a systematic review and meta-analysis. JAMA Network Open. 2018;1(5):e182421; Metabolic equivalent. Wikipedia. https://en.wikipedia.org/wiki/ Metabolic_equivalent. Accessed October 15, 2018.
54. Serra-Majem L, Roman B, Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systemic review. Nutritional Review. 2006;64:S27-S47; Casini A, Gensini GF, Abbate R, Sofi F. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. American Journal of Clinical Nutrition. 2010;92(5):1189–1196.
55. Casini A, Gensini GF, Abbate R, Sofi F. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. American Journal of Clinical Nutrition. 2010;92(5):1189–1196.
56. Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson’s disease. Movement Disorders. 2012;27(6):771–774.
57. Gao X, Chen H, Fung TT, et al. Prospective study of dietary pattern and risk of Parkinson disease. American Journal of Clinical Nutrition. 2007;86(5):1486–1494.
58. Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson’s disease. Movement Disorders. 2012;27(6):771–774; Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ. 2008;337.
59. Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson’s disease. Movement Disorders. 2012;27(6):771–774.
60. Gao X, Chen H, Fung TT, et al. Prospective study of dietary pattern and risk of Parkinson disease. American Journal of Clinical Nutrition. 2007;86(5):1486–1494.
61. Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes. Biochimica et Biophysica Acta. 2014;1842(8):1282–1294.
62. Ross G, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283(20):2674–2679; Paganini-Hill A. Risk factors for Parkinson’s disease: the leisure world cohort study. Neuroepidemiology. 2001;20(2):118–124; Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Annals of Neurology. 2001;50(1):56–63; Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A metaanalysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Annals of Neurology. 2002;52(3):276–284; Tan LC, Koh WP, Yuan JM, et al. Differential effects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. American Journal of Epidemiology. 2008;167(5):553–560; Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. American Journal of Epidemiology. 2012;175(11):1200–1207.
63. Ross G, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283(20):2674–2679.
64. Там же.; Munoz DG, Fujioka S. Caffeine and Parkinson disease: a possible diagnostic and pathogenic breakthrough. Neurology. 2018;90(5):205–206.
65. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Annals of Neurology. 2001;5O(1):56–63.
66. Munoz DG, Fujioka S. Caffeine and Parkinson disease: A possible diagnostic and pathogenic breakthrough. Neurology. 2O18;9O(5):2O5-206; Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology. 2002;58(8):1154–1160.
67. Postuma RB, Anang J, Pelletier A, et al. Caffeine as symptomatic treatment for Parkinson disease (Caffi-PD): a randomized trial. Neurology. 2017;89(17):1795–1803.
68. Palacios N, Gao X, McCullough ML, et al. Caffeine and risk of Parkinson’s disease in a large cohort of men and women. Movement Disorders. 2012;27(10):1276–1282.
69. Wikoff D, Welsh BT, Henderson R, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food and Chemical Toxicology. 2017;109:585–648.
Глава 7: Уход
1. JG. JCC Greater Boston – building a new beginning [видео]. YouTube. March 23, 2018. www.youtube.com/watch?v=unw3Ue2DWME.
2. Lagro-Janssen ALM, van den Heuvel EAJ, Bor HH, et al. Prodromal symptoms and early detection of Parkinson’s disease in general practice: a nested case-control study. Family Practice. 2014;31(4):373–378; Gonera EG, Hof MVt, Berger HJC, van Weel C, Horstink MWIM. Symptoms and duration of the prodromal phase in Parkinson’s disease. Movement Disorders. 1997;12(6):871–876.
3. Osler W, Sir. The Principles and Practice of Medicine. D. Appleton and Company; 1892.
4. Taylor KSM, Counsell CE, Harris CE, Gordon JC. Screening for undiagnosed parkinsonism in people aged 65 years and over in the community. Parkinsonism & Related Disorders. 2006;12(2):79–85.
5. Nicoletti A, Sofia V, Bartoloni A, et al. Prevalence of Parkinson’s disease: a door-to-door survey in rural Bolivia. Parkinsonism & Related Disorders. 2003;10(1):19–21.
6. Kis B, Schrag A, Ben-Shlomo Y, et al. Novel three-stage ascertainment method: prevalence of PD and parkinsonism in South Tyrol, Italy. Neurology. 2002;58(12):1820–1825.
7. Muangpaisan W, Hori H, Brayne C. Systematic review of the prevalence and incidence of Parkinson’s disease in Asia. Journal of Epidemiology. 2009;19(6):281–293.
8. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology. 1985;35(6):841–845.
9. Safarpour D, Thibault DP, DeSanto CL, et al. Nursing home and end-of-life care in Parkinson disease. Neurology. 2015;85(5):413–419.
10. Buchanan RJ, Wang S, Huang C, Simpson P, Manyam BV. Analyses of nursing home residents with Parkinson’s disease using the minimum data set. Parkinsonism & Related Disorders. 2002;8(5):369–380.
11. Weerkamp NJ, Zuidema SU, Tissingh G, et al. Motor profile and drug treatment of nursing home residents with Parkinson’s disease. Journal of the American Geriatrics Society. 2012;60(12):2277–2282.
12. Safarpour D, Thibault DP, DeSanto CL, et al. Nursing home and end-of-life care in Parkinson disease. Neurology. 2015;85(5):413–419.
13. Weerkamp NJ, Tissingh G, Poels PJE, et al. Diagnostic accuracy of Parkinson’s disease and atypical parkinsonism in nursing homes. Parkinsonism & Related Disorders. 2014;20(11):1157–1160.
14. Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology. 2011;77(9):851–857.
15. Там же.
16. Там же.
17. Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA. 2018;319(10): 10241039; Dahodwala N, Xie M, Noll E, Siderowf A, Mandell DS. Treatment disparities in Parkinson’s disease. Annals of Neurology. 2009;66(2):142–145.
18. Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology. 2011;77(9):851–857.
19. Willis AW, Schootman M, Kung N, Wang X-Y, Perlmutter JS, Racette BA. Disparities in deep brain stimulation surgery among insured elders with Parkinson disease. Neurology. 2014;82(2):163–171.
20. Willis AW, Schootman M, Tran R, et al. Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. Neurology. 2012;79(17):1774–1780.
21. Gage H, Hendricks A, Zhang S, Kazis L. The relative health related quality of life of veterans with Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2003;74(2):163–169.
22. Seidman C. Caring for wife with dementia leads husband to contemplate suicide. Sarasota Herald-Tribune. July 12, 2018; Opinion.
23. Caregiving in the U.S. 2015—executive summary. National Alliance for Caregiving. June 2015. www.caregiving.org/wp-content/ uploads/2015/05/2015_CaregivingintheUS_Executive-Summary-June-4 WEB.pdf. Accessed June 27, 2019.